Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test

Active, not recruitingOBSERVATIONAL
Enrollment

307

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome
Trial Locations (10)

10032

Columbia University Irving Medical Center, New York

30912

Georgia Cancer Center at Augusta University, Augusta

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

44195

Cleveland Clinic Foundation, Cleveland

63110

Washington University in St. Louis, St Louis

84112

University of Utah, Salt Lake City

91010

City of Hope, Duarte

94005

University of California Irvine, Brisbane

97239

Oregon Health & Science University, Portland

02215

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CareDx

INDUSTRY

NCT04635384 - Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test | Biotech Hunter | Biotech Hunter